Allogene Therapeutics, Inc (ALLO)

Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the The Materials Select Sector SPDR Fund, where 4,050,000 units were destroyed, or a 4.4% decrease week over week. Among the largest underlying components of XLB, in morning trading today Linde is off about 0.3%, and Sherwin-williams is lower by about 0.1%.

These two novel-drug makers could be top takeover targets next year.

Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

Investors in Allogene Therapeutics Inc (ALLO) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALLO options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

A key gene-editing readout had Cathie Wood shuffling her portfolio.

The ARK Innovation ETF and ARK Genomic Revolution ETF cumulatively snapped up hundreds of thousands of shares in Crispr in the past week.

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.

Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: Bullish Somewhat ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

In this article we are going to estimate the intrinsic value of Allogene Therapeutics, Inc. ( NASDAQ:ALLO ) by...

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allogene Therapeutics, Inc. ("Therapeutics" or the "Company") (NASDAQ: ALLO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com,

Companies in The News Are: ACCD,CCXI,ALLO,WMT

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s ...

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ralph Lauren Corp (RL), where a total of 15,797 contracts have traded so far, representing approximately 1.6 million underlying shares. That amounts to about 204.9% of RL's average daily trading volume over the past month of 771,125 shares..

Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, ...

The broader market was mixed on Friday.

A possible safety issue is crushing the biotech's shares today.

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 ...

Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, ...

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: ...

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) ...

Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:NTRS) from Neutral to Buy. Northern Trust earned $1.79 in ...

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also ...

Barclays cut the price target on Constellation Brands, Inc. (NYSE: STZ) from $260 to $257. Constellation Brands shares fell 0.3% to ...